GENOMIC CHARACTERIZATION OF PROSTATIC BASAL CELL CARCINOMA.
暂无分享,去创建一个
G. Ha | A. D. De Marzo | J. Epstein | W. Nelson | John K. Lee | S. Yegnasubramanian | M. Haffner | C. Heaphy | Shan Li | Michael C. Haffner | J. Low | Minjeong Ko | Anuj Gupta | B. Hanratty | A. Bhamidipati | E. Sayar | Radhika A. Patel | Erolcan Sayar
[1] A. M. Houghton,et al. Loss of MGA repression mediated by an atypical polycomb complex promotes tumor progression and invasiveness , 2021, eLife.
[2] Astrid Gall,et al. Ensembl 2021 , 2020, Nucleic Acids Res..
[3] Ze-Guang Han,et al. Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma. , 2020 .
[4] M. Meyerson,et al. Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma , 2019, Molecular Cancer Research.
[5] Shuhong Zhao,et al. Prostate Luminal Progenitor Cells in Development and Cancer. , 2018, Trends in cancer.
[6] Christopher T. Saunders,et al. Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.
[7] Christopher W. Whelan,et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing , 2018, Cell.
[8] C. Sander,et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets , 2018, Nature Genetics.
[9] Yi Mi Wu,et al. The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.
[10] Nikhil Wagle,et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors , 2017, Nature Communications.
[11] P. Humphrey,et al. Histopathology of Prostate Cancer. , 2017, Cold Spring Harbor perspectives in medicine.
[12] J. Isaacs,et al. Low p16INK4a Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone , 2017, The Prostate.
[13] P. McPherson,et al. Regulation of DENND3, the exchange factor for the small GTPase Rab12 through an intramolecular interaction , 2017, The Journal of Biological Chemistry.
[14] Joachim Weischenfeldt,et al. SvABA: genome-wide detection of structural variants and indels by local assembly , 2018, Genome research.
[15] V. W. Lui,et al. The cylindromatosis (CYLD) gene and head and neck tumorigenesis , 2016, Cancers of the Head & Neck.
[16] R. Huddart,et al. The genomic landscape of testicular germ cell tumours: from susceptibility to treatment , 2016, Nature Reviews Urology.
[17] R. Levine,et al. Molecular therapy for acute myeloid leukaemia , 2016, Nature Reviews Clinical Oncology.
[18] A. Ashworth,et al. Inherited cylindromas: lessons from a rare tumour. , 2015, The Lancet. Oncology.
[19] J. Epstein,et al. A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma. , 2015, Human pathology.
[20] Nitin Patel,et al. Expression and Functional Role of Orphan Receptor GPR158 in Prostate Cancer Growth and Progression , 2015, PloS one.
[21] Sohrab P. Shah,et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data , 2014, Genome research.
[22] Masashi Kato,et al. Basal cell carcinoma arising in the prostate , 2014, International journal of urology : official journal of the Japanese Urological Association.
[23] Z. Xiong,et al. Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells. , 2014, International journal of clinical and experimental pathology.
[24] Hualiang Jiang,et al. Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility. , 2014, Carcinogenesis.
[25] M. Rubin,et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.
[26] Aaron R Cooper,et al. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells , 2013, Proceedings of the National Academy of Sciences.
[27] N. Kübler,et al. Cylindroma of head and neck: review of the literature and report of two rare cases. , 2013, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.
[28] J. Carette,et al. A Reporter Screen in a Human Haploid Cell Line Identifies CYLD as a Constitutive Inhibitor of NF-κB , 2013, PloS one.
[29] W. Isaacs,et al. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer , 2013, The Journal of pathology.
[30] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[31] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[32] M. Heinrich,et al. Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.
[33] David Heckerman,et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.
[34] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[35] J. Jorcano,et al. An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells , 2010, Oncogene.
[36] Jiaoti Huang,et al. Identification of a Cell of Origin for Human Prostate Cancer , 2010, Science.
[37] Martin J. Aryee,et al. Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.
[38] M. Soloway,et al. Basal cell carcinoma of the prostate: current concepts , 2007, BJU international.
[39] J. Epstein,et al. Basal Cell Carcinoma of the Prostate: A Clinicopathologic Study of 29 Cases , 2007, The American journal of surgical pathology.
[40] G. Fuller,et al. A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors , 2005, Oncogene.
[41] T. Schlomm,et al. Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach , 2005, Virchows Archiv.
[42] Shao-Cong Sun,et al. Negative Regulation of JNK Signaling by the Tumor Suppressor CYLD* , 2004, Journal of Biological Chemistry.
[43] D. Grignon,et al. Basal Cell Proliferations of the Prostate Other Than Usual Basal Cell Hyperplasia: A Clinicopathologic Study of 23 Cases, Including Four Carcinomas, With a Proposed Classification , 2004, The American journal of surgical pathology.
[44] D. Bostwick,et al. Adenoid Cystic/Basal Cell Carcinoma of the Prostate: Clinicopathologic Findings in 19 Cases , 2003, The American journal of surgical pathology.
[45] René Bernards,et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB , 2003, Nature.
[46] G. Courtois,et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination , 2003, Nature.
[47] P. Humphrey,et al. Basal Cell Hyperplasia in the Peripheral Zone of the Prostate , 2003, Modern Pathology.
[48] Maria Merino,et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.
[49] J. Fletcher,et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.
[50] A. Ashworth,et al. Identification of the familial cylindromatosis tumour-suppressor gene , 2000, Nature Genetics.
[51] N. Jenkins,et al. Mga, a dual‐specificity transcription factor that interacts with Max and contains a T‐domain DNA‐binding motif , 1999, The EMBO journal.
[52] Ximing J. Yang,et al. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67. , 1998, Human pathology.
[53] D. S. Coffey,et al. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. , 1998, The American journal of pathology.
[54] Bruno Amati,et al. Oncogenic activity of the c-Myc protein requires dimerization with Max , 1993, Cell.
[55] D. Grignon,et al. Basal cell hyperplasia, adenoid basal cell tumor, and adenoid cystic carcinoma of the prostate gland: an immunohistochemical study. , 1988, Human pathology.
[56] Ximing J. Yang,et al. MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia , 2019, Modern Pathology.
[57] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..